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ABSTRACT
Introduction: In phase III trials in adolescents
and children with atopic dermatitis (AD),
dupilumab significantly decreased global dis-
ease severity. However, the effects of dupilumab
on the extent and signs of AD across different
anatomical regions were not reported. Here we
characterize the efficacy of dupilumab in
improving the extent and signs of AD across
four different anatomical regions in children
and adolescents.
Methods: A post hoc subset analysis was per-
formed using data from two randomized, dou-
ble-blind, placebo-controlled, international
multicenter, phase III trials of dupilumab ther-Supplementary Information The online versioncontains supplementary material available at https://doi.
org/10.1007/s13555-021-00568-y.
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apy in adolescents aged C 12 to\18 years with
moderate-to-severe AD and children aged C 6
to\12 years with severe AD. Endpoints inclu-
ded mean percentage change in Eczema Area
and Severity Index (EASI) signs (erythema,
edema/papulation, excoriation, lichenification)
and extent of AD (measured by percentage of
body surface area [% BSA] involvement) from
baseline to week 16 across four anatomical
regions (head and neck, trunk, upper extremi-
ties, lower extremities).
Results: Dupilumab improved both the extent
and severity of AD signs across the four
anatomical regions. Improvements were shown
to be similar across the four anatomical regions
for % BSA involvement and for reduction in
EASI signs. Improvements in all signs were seen
early, within the first 4 weeks of treatment, and
were sustained through week 16, across all
regions.
Conclusions: In pediatric patients 6 years of age
and older, treatment with dupilumab resulted
in rapid and consistent improvement in the
extent and signs of AD across all anatomical
regions.
ClinicalTrials.gov Identifiers: LIBERTY AD
ADOL (NCT03054428) and LIBERTY AD PEDS
(NCT03345914).
Keywords: Atopic eczema; Dupilumab;
Pediatric dermatology; Patients; Immunology;
Cytokines; Contact dermatitis; Anatomical
regions; Facial erythema; Signs
Key Summary Points
Why carry out this study?
In phase III trials in adults and adolescents
with moderate-to-severe atopic dermatitis
(AD) and children 6 years of age and older
with severe AD, treatment with
dupilumab resulted in a substantial
reduction in disease severity.
In adults, improvements were shown to be
similar across anatomical regions.
This study aimed to characterize the
efficacy of dupilumab in improving the
extent and signs of AD across four
different anatomical regions in children
and adolescents.
What was learned from the study?
This study reports the effect of dupilumab
across different anatomical regions in
pediatric patients 6 years of age and older.
Dupilumab demonstrated rapid and
consistent improvement for 16 weeks in
the extent and signs of atopic dermatitis
across all anatomical regions.
DIGITAL FEATURES
This article is published with digital features,
including a video summary, to facilitate
understanding of the article. To view digital
features for this article go to https://doi.org/10.
6084/m9.figshare.14779038.
INTRODUCTION
Atopic dermatitis (AD) is characterized by dis-
tinct distribution patterns in different age
groups, but with some interpatient variation
with regard to the most severely affected sites
[1–3]. In some cases, this represents a secondary
condition. For example, the face, feet, and
hands are common sites for exacerbation by
irritants or allergic contact dermatitis [1, 2, 4],
while Malassezia colonization may trigger
exacerbation on the face and neck, especially in
adolescents [5]. Sun-exposed sites can also be
exacerbated by photosensitivity [6, 7].
Some anatomical regions may have a greater
impact on quality of life than others [8, 9]. The
face and hands, for example, are highly visible,
aesthetically important sites. Palmar involve-
ment can interfere with function and plantar
involvement with ambulation [9, 10]. Affected
skin folds can be painful.
The anatomical location of AD can also
impact treatment options. Although topical
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corticosteroids (TCS) are the mainstay treat-
ment for AD, prolonged use on the face can
trigger rosacea and perioral dermatitis, while
use on skin folds carries a higher risk of striae
[11]. Steroid withdrawal can result in rebound
erythema on the facial regions [12]. Skin atro-
phy can occur, especially on the eyelids and
intertriginous areas [13, 14]. Thicker skin on
palms and soles may require use of higher-po-
tency TCS for optimal response, with increased
risk of atrophy and rebound effects [2, 11]. The
tissue distribution and response to systemic
medication, including biologics, may be differ-
ent across anatomical areas owing to regional
differences in skin blood flow [15].
Dupilumab is a fully human monoclonal
antibody that blocks the shared receptor com-
ponent for interleukin (IL)-4 and IL-13,
inhibiting signaling of both IL-4 and IL-13
[16, 17], which are key drivers of type 2-medi-
ated inflammation in multiple diseases [16, 18].
The Eczema Area and Severity Index (EASI)
and evaluation of percentage body surface area
(BSA) affected permit assessment of AD clinical
severity by defined anatomical region based on
four signs (erythema, edema/papulation, exco-
riation, and lichenification) [19, 20]. Previous
analyses of data from phase III trials in adults
with moderate-to-severe AD showed that sig-
nificant disease severity improvement from
dupilumab was similar in all anatomical regions
as assessed by EASI [21]. Improvements were
seen as early as week 4, and were maintained up
to week 52 [21].
Phase III trials in 251 adolescents aged C 12
to\18 years with moderate-to-severe AD [22]
and in 367 children aged C 6 to\ 12 years with
severe AD [23] treated with dupilumab demon-
strated substantial improvements in global dis-
ease severity and BSA affected with an
acceptable safety profile. However, efficacy
across different anatomical regions was not
reported.
The objective of this study was to assess the
efficacy of dupilumab in improving the extent
and severity of AD signs (erythema,
edema/papulation, excoriation, lichenification)
in four anatomical regions (head and neck,
trunk, upper extremities, lower extremities) in
pediatric patients aged 6 years and older.
METHODS
We performed a post hoc analysis of data from
two randomized, double-blind, parallel group,
placebo-controlled, global, phase III trials of
dupilumab: LIBERTY AD ADOL (NCT03054428)
[22] and LIBERTY AD PEDS (NCT03345914)
[23]. The full study designs and patient popu-
lations of the trials have been previously
reported [22, 23].
Briefly, LIBERTY AD ADOL included adoles-
cent patients aged C 12 to\ 18 years with
moderate-to-severe AD inadequately controlled
by topical medications or for whom topical
treatment was medically inadvisable [22].
Patients were required to have minimum overall
BSA of AD involvement at screening and base-
line of 10%; there was no requirement for
minimum BSA of involvement in a specific
anatomical region. Patients were randomized
1:1:1 to placebo, dupilumab 300 mg every
4 weeks (q4w; with a loading dose of 600 mg),
or dupilumab every 2 weeks (q2w; 200 mg with
a loading dose of 400 mg if body
weight\60 kg, or 300 mg with a loading dose
of 600 mg if body weight C 60 kg). Systemic
nonsteroidal immunosuppressants, systemic
corticosteroids or TCS, topical calcineurin
inhibitors, and topical crisaborole were only
allowed for use as rescue treatment for patients
with intolerable AD symptoms at the discretion
of the investigator. Assessments, including
patient-reported outcomes and investigator-
performed assessments, to evaluate treatment
effect were based on overall AD disease severity
without any further prespecified analysis to
assess efficacy individually in different
anatomical regions.
LIBERTY AD PEDS included children aged
C 6 to\12 years with severe AD inadequately
controlled by topical medications [23]. Mini-
mum overall BSA of AD involvement at
screening and baseline of 15% was required,
without any requirement for minimum BSA of
involvement in a specific anatomical region.
Patients were randomized 1:1:1 to placebo,
dupilumab 300 mg q4w (loading dose of
600 mg) or dupilumab q2w (100 mg with a
loading dose of 200 mg if body weight\ 30 kg,
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Table 1 Baseline characteristics: EASI regional scores (weighted for % BSA) and % BSA affected
Score
range










































EASI score, mean (SD) 0–72 37.9 (12.1) 38.9 (12.6) 36.9 (12.4) 39.0 (11.5) 37.1 (11.8) 37.8 (12.6) 35.4 (13.9) 35.0 (15.5) 36.1 (14.6) 36.0 (12.4) 34.4 (13.1)
EASI regional score,






3.8 (2.8) 5.3 (3.4) 4.8 (3.3) 2.9 (1.6) 3.0 (1.9) 2.9 (2.1) 2.8 (1.6) 2.9 (1.6) 2.7 (1.7) 2.7 (1.7) 2.8 (1.5)
Trunk, mean (SD) 0–21.6 8.8 (5.3) 9.0 (5.4) 8.7 (5.1) 9.6 (4.9) 8.2 (5.7) 8.5 (5.4) 9.2 (5.4) 9.0 (6.0) 8.8 (5.7) 9.7 (5.2) 9.1 (4.6)
Upper extremities,
mean (SD)































































































































BSA body surface area, EASI Eczema Area and Severity Index, Q1–Q3 interquartile range, q2w every 2 weeks, q4w every 4 weeks, SD standard deviation, TCS topical corticosteroid
a For children aged\ 8 years, % BSA weighting coefficient is 0.2 for head and neck, 0.3 for trunk, 0.2 for upper extremities, and 0.3 for lower extremities. For children aged C 8 years, % BSA weighting coefficient is 0.1 for head and
neck, 0.3 for trunk, 0.2 upper extremities, and 0.4 for lower extremities
b For children aged\ 8 years in LIBERTY AD PEDS
































or 200 mg with a loading dose of 400 mg if body
weight C 30 kg). All patients received medium-
potency TCS starting 2 weeks before baseline,
with a possibility to escalate to high-potency
TCS as rescue treatment; the use of very high-
potency TCS was prohibited. On the basis of
investigator discretion, low-potency TCS were
allowed to be used once daily on areas of thin
skin (face, neck, intertriginous and genital
areas, and areas of skin atrophy, etc.) or for areas
where continued treatment with medium-po-
tency TCS was considered unsafe. Use of topical
calcineurin inhibitors was prohibited. Assess-
ments, including patient-reported outcomes
and investigator-performed assessments, to
evaluate treatment effects were based on overall
AD disease severity without any further pre-
specified analysis to assess efficacy individually
in different anatomical regions.
Both trials were conducted in accordance
with the provisions of the Declaration of Hel-
sinki, the International Conference on Har-
monisation Good Clinical Practice guidelines,
and applicable regulatory requirements. The
study protocols were reviewed and approved by
institutional review boards or ethics committees
at all study sites. For all patients, at least one
parent or legal guardian provided written
informed assent, and patients provided written
informed assent before study participation.
Endpoints
Least squares (LS) mean percentage change in
EASI from baseline to week 16 by visit and the
median percentage change in BSA affected from
baseline to week 16 by visit were evaluated in
the four anatomical regions (head and neck,
trunk, upper extremities, lower extremities). As
a result of the non-normal distribution of % BSA
data and to reduce the impact of outliers, an
analysis using median percentage change
(rather than mean percentage change) from
baseline was performed. The median difference
and 95% confidence interval (CI) were calcu-
lated with the Hodges–Lehmann method. The
median estimates and 95% CI were calculated
with the quantile regression method.
BSA was calculated using the rule of nines
and combined in the four regions as follows:
head and neck (0–9%), trunk (0–36%), upper
right plus upper left extremities (0–18%), and
lower right plus lower left extremities plus
genitalia (0–37%).
LS mean percentage change from baseline in
EASI signs (erythema, edema/papulation, exco-
riation, and lichenification) was evaluated in
the four anatomical regions. EASI sign scores
were calculated as a composite of the intensity
(0–3) and extent of involvement (0–6). For each
region, the intensity of signs (erythema,
edema/papulation, excoriation, lichenification)
was summated (0–12) and then multiplied by
extent of involvement (0–6). These scores were
presented as both weighted and nonweighted
scores. For weighting, the % BSA assigned to
each anatomical region in the EASI score cal-
culation was used [24]. For children
aged\8 years, the % BSA weighting coefficient
used was 0.2 for head and neck, 0.3 for trunk,
0.2 for upper extremities, and 0.3 for lower
extremities. For children aged C 8 years, the
% BSA weighting coefficient used was 0.1 for
head and neck, 0.3 for trunk, 0.2 upper
extremities, and 0.4 for lower extremities.
Analysis
Only data from LIBERTY AD ADOL and LIB-
ERTY AD PEDS for patients receiving dupilumab
doses approved by the US Food and Drug
Administration and European Medicines
Agency (dupilumab 300 mg q4w for body
weight\30 kg; 300 mg q4w for body
weight C 30 kg; 200 mg q2w for body weight
C 30 to\ 60 kg or 300 mg q2w for body
weight C 60 kg) or corresponding placebo were
included in this analysis. All patients random-
ized to the approved dupilumab doses were
included in efficacy analyses.
Endpoints were analyzed using an analysis of
covariance (ANCOVA) model with baseline
measurement as covariate and the treatment,
randomization strata (baseline disease severity
[Investigator’s Global Assessment (IGA) = 3 vs.
IGA = 4] for LIBERTY AD ADOL only), and
geographical region (North America vs. Europe
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Table 2 Baseline characteristics: EASI erythema, infiltration/papulation, excoriation, and lichenification scores
Score
range








































0–18 8.0 (4.5) 8.8 (5.0) 8.4 (4.6) 7.9 (4.3) 7.6 (3.8) 7.4 (4.8) 8.2 (4.4) 8.6 (4.3) 7.8 (4.5) 8.0 (5.1) 8.2 (3.7)
Trunk,
mean (SD)
0–18 7.8 (4.6) 7.7 (4.7) 7.6 (4.6) 8.4 (4.4) 7.4 (4.7) 7.9 (4.9) 8.2 (4.8) 7.7 (5.1) 7.8 (5.1) 8.7 (4.6) 8.6 (4.2)
Upper extremities,
mean (SD)
0–18 10.9 (3.8) 10.9 (3.7) 10.2 (4.0) 11.4 (3.9) 10.5 (3.5) 11.5 (3.8) 10.1 (4.2) 10.3 (4.2) 9.7 (4.4) 10.5 (3.9) 9.9 (4.2)
Lower extremities,
mean (SD)




0–18 6.9 (4.3) 7.3 (4.48) 7.5 (4.3) 6.6 (4.2) 6.5 (4.1) 6.5 (4.5) 7.1 (4.3) 7.6 (4.2) 7.1 (4.4) 6.5 (4.5) 7.3 (4.1)
Trunk,
mean (SD)
0–18 7.7 (4.8) 8.0 (4.76) 7.6 (4.6) 8.5 (4.5) 7.1 (5.2) 7.4 (4.8) 7.9 (4.6) 8.0 (5.1) 7.5 (4.9) 8.2 (4.4) 8.1 (4.1)
Upper extremities,
mean (SD)
0–18 10.9 (3.7) 11.1 (3.9) 10.3 (3.7) 11.4 (3.9) 10.4 (3.7) 11.3 (3.4) 10.1 (4.1) 10.5 (4.5) 9.4 (3.8) 10.3 (3.9) 10.1 (4.2)
Lower extremities,
mean (SD)




0–18 6.1 (4.5) 6.6 (4.8) 6.7 (4.7) 6.1 (4.5) 5.3 (3.7) 5.7 (4.5) 6.0 (4.7) 5.9 (4.8) 6.0 (5.0) 6.0 (4.8) 6.0 (4.5)
Trunk,
mean (SD)
0–18 6.7 (4.8) 6.7 (4.9) 6.7 (4.6) 7.3 (4.8) 6.5 (5.2) 6.5 (4.6) 7.3 (5.0) 7.3 (5.4) 7.1 (5.4) 7.9 (4.7) 7.0 (4.6)
Upper extremities,
mean (SD)
0–18 10.6 (4.1) 10.7 (4.3) 10.3 (4.1) 10.8 (4.2) 10.1 (4.2) 11.1 (3.9) 9.9 (4.3) 10.2 (4.6) 9.3 (4.3) 10.4 (3.7) 9.9 (4.5)
Lower extremities,
mean (SD)




0–18 7.0 (4.6) 7.4 (4.5) 7.8 (4.9) 6.7 (4.3) 6.8 (4.4) 6.2 (4.9) 6.5 (4.2) 7.1 (4.7) 6.1 (4.3) 6.0 (4.2) 6.6 (3.7)
Trunk,
mean (SD)
0–18 7.1 (4.7) 7.6 (4.6) 7.2 (4.5) 7.8 (4.9) 6.5 (4.8) 6.5 (5.0) 7.1 (4.9) 7.2 (5.4) 7.1 (4.7) 7.4 (5.5) 6.7 (4.2)
Upper extremities,
mean (SD)
0–18 11.1 (3.8) 11.3 (3.9) 10.7 (3.9) 11.5 (3.8) 10.9 (3.3) 11.3 (3.8) 10.0 (4.5) 9.8 (5.0) 10.0 (4.4) 10.3 (4.5) 10.0 (4.2)
Lower extremities,
mean (SD)
0–18 11.6 (4.1) 12.6 (3.7) 11.2 (4.3) 11.8 (4.1) 11.1 (3.7) 11.1 (4.4) 9.5 (4.8) 9.4 (5.1) 10.6 (4.6) 9.3 (4.9) 8.7 (4.3)
































for LIBERTY AD PEDS only) as fixed factors.
Values after rescue medication use were set to
missing. For LS mean percentage change in
EASI, EASI signs, and median percentage change
in BSA affected, missing values were imputed
using the last observation carried forward
method. p\ 0.05 (two-sided tests) was regarded
as significant. Statistical Analysis Software, ver-
sion 9.4 (SAS Institute, Inc; Cary, NC, USA) was
used for all analyses.
RESULTS
In the LIBERTY AD ADOL study, 251 patients
were randomized (mean age 14.5 years; 59%
male) [22], and in LIBERTY AD PEDS, 367
patients were randomized (mean age approxi-
mately 8.5 years; 49.9% male) [23]. A total of
167 patients from LIBERTY AD ADOL and 304
patients from LIBERTY AD PEDS were included
in this analysis (patients who received approved
dupilumab doses, and body-weight-matched
placebo control patients).
EASI scores and component scores were bal-
anced at baseline between the treatment groups
in each individual study (Tables 1 and 2). The
overall EASI score as well as the regional scores
were comparable between the dupilumab and
placebo arms across both studies at baseline. On
comparing the EASI regional scores at baseline,
there was a trend towards higher disease sever-
ity on the upper and lower extremities com-
pared with the head and neck, and trunk
regions (43.5 and 45.4 vs. 28.0 and 29.4,
respectively, in LIBERTY AD PEDS; 40.1 and
38.6 vs. 27.7 and 30.5, respectively, in LIBERTY
AD ADOL) (Fig. 1; Table S1 in the Supplemen-
tary Material).
Overall, all dupilumab regimens vs. the cor-
responding placebo regimen significantly
improved EASI score across the four anatomical
regions during 16 weeks of treatment (Figs. 1
and 2). In LIBERTY AD PEDS, a significant
improvement was seen with dupilumab as early
as week 1 in head and neck, trunk, and upper
extremities scores, and as early as week 2 in
lower extremities scores, with improvements in
all EASI scores and anatomical regions sustained
through week 16. In LIBERTY AD ADOL, a
significant improvement vs. placebo was seen in
all four anatomical regions as early as week 2,
with improvements sustained through week 16.
Median percentage change in BSA affected
from baseline to week 16 by visit in four
anatomical regions is shown in Fig. 3. Overall,
all dupilumab regimens vs. the corresponding
placebo regimen significantly improved the
extent of lesions as measured by improvements
in % BSA across the four anatomical regions
during 16 weeks of treatment.
Overall, all dupilumab regimens vs. the cor-
responding placebo regimens significantly
improved EASI signs score across the four
anatomical regions during 16 weeks of treat-
ment, including lichenification, the AD sign
most resistant to treatment [25] (Fig. 4;
Figs. S1–S3 in the Supplementary Material).
Although statistical significance for lichenifica-
tion was not seen for the dupilumab 300 mg
q4w ? TCS C 30 kg for the head and neck
region at week 16, the dupilumab treatment
showed numerically higher improvement as
compared with placebo. Moreover, a statisti-
cally significant difference was seen at week 12.
Regarding erythema (Fig. 4) in LIBERTY AD
ADOL, a significant improvement in head and
neck with dupilumab was seen as early as
week 1, and in trunk, lower extremities, and
upper extremities as early as week 2. In LIBERTY
AD PEDS a significant improvement vs. placebo
in head and neck and trunk was seen with
dupilumab as early as week 2, and in the upper
and lower extremities as early as week 3.
Regarding infiltration/papulation, excoriation,
and lichenification (Figs. S1, S2, and S3,
respectively, in the Supplementary Material),
significant improvements in all measures asses-
sed vs. the corresponding placebo groups were
seen with both dupilumab regimens within the
first 4 weeks of treatment.
DISCUSSION
In this analysis of data from two randomized,
double-blind, placebo-controlled, phase III tri-
als in adolescents with moderate-to-severe AD
and children with severe AD, dupilumab rapidly
improved the extent and severity of AD signs
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across four anatomical regions (head and neck,
trunk, upper extremities, lower extremities).
The disease burden at baseline was comparable
across treatment groups. However, the baseline
disease burden was numerically higher in upper
and lower extremities compared with trunk and
head and neck. This is consistent with flexural
areas, wrists, ankles, hands and feet, being
favored sites for AD [26]. Moreover, this pattern
was seen consistently in younger children as
well as adolescents. This was expected, as
childhood (seen in pre-pubertal children) and
adult forms (seen in post-pubertal children and
adults) have been reported to have similar dis-
tributions as opposed to infantile forms, which
tend to favor the face, scalp, and trunk [27].
Dupilumab reduced the extent of AD across the
four anatomical regions (measured by % BSA)
and improved erythema, edema/papulation,
excoriation, and lichenification (measured by
EASI).
The dupilumab dosing regimens assessed in
children and adolescents yielded similar EASI
and % BSA improvements across all four
anatomical regions, reflecting comparable
results seen in adults with moderate-to-severe
AD who received dupilumab with or without
TCS [21]. Signs of inflammation mimicking AD
can suggest another etiology based on their
distribution, such as superimposed contact
dermatitis involving the face, hands, and feet,
photodistributed reactions, and Malassezia col-
onization involving the face and neck
[4, 6, 28, 29]. However, a 16-week course of
dupilumab in over 200 pediatric patients yiel-
ded similar improvement across all regions,
suggesting that nonatopic confounding causes
of inflammation are uncommon during the first
Fig. 1 Analysis of value in EASI regional scoresa (from
baseline to week 16)b. aEASI regional scores nonweighted
for % BSA. bFor graphical purposes, figures have been
constructed to represent the right side of the body being
treated with placebo and the left side being treated with
dupilumab. In patients receiving dupilumab, similar
responses were achieved on both sides of the body. BSA
body surface area, EASI Eczema Area and Severity Index,
LS least squares, q2w every 2 weeks, q4w every 4 weeks,
TCS topical corticosteroid
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4 months of treatment. On the basis of reports
in the literature, dupilumab may have a bene-
ficial effect on some of these co-existing eti-
ologies, especially allergic contact dermatitis
[30–33].
The dupilumab regimens assessed here
showed improvement in all EASI signs.
Improvements in all regions and signs were seen
early, after the first or second dupilumab dose,
and were sustained through week 16. Although
there have been published case series in patients
with AD showing apparent new-onset dupilu-
mab-induced facial erythema associated with a
spectrum of proposed causes [34–38], in the
present analysis the improvements in erythema
scores for the head and neck region were com-
parable with those seen for other signs and
anatomical regions. This observation, coupled
with the finding that the improvement in
regional EASI scores was similar across different
Fig. 2 LS mean percentage change in EASI regional scorea
from baseline to week 16 by visit in four anatomical
regions. *p\ 0.05; **p\ 0.001; ***p\ 0.0001; vs. corre-
sponding placebo. aEASI regional scores weighted for
% BSA. BSA body surface area, EASI Eczema Area and
Severity Index, LS least squares, q2w every 2 weeks, q4w
every 4 weeks, SE standard error, TCS topical
corticosteroid
Fig. 3 Median percentage change in BSA affecteda from
baseline to week 16 by visit in four anatomical regions.
*p\ 0.05; **p\ 0.001; ***p\ 0.0001; vs. corresponding
placebo. aThe median difference and 95% CI were
calculated with the Hodges–Lehmann method. The
median estimates and 95% CI were calculated with the
quantile regression method. BSA body surface area, CI
confidence interval, q2w every 2 weeks, q4w every 4 weeks,
TCS topical corticosteroid
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anatomical regions including head and neck,
suggests that these instances of dupilumab-in-
duced erythema are unlikely to reflect AD
lesions that did not respond to dupilumab
treatment. Alternatively, worsening facial ery-
thema may be too rare, 4% of patients in one
study [35], and not covering enough surface
area to be able to be detected by the EASI head
and neck region score for a relatively small
population of patients.
The efficacy results are accompanied by a
safety profile consistent with the primary anal-
yses of the trials: dupilumab was generally well
tolerated with an acceptable safety profile
[22, 23, 39]. An ongoing phase III study in
adults and adolescents with AD affecting hands
and feet (NCT04417894) will further evaluate
the effect of dupilumab on these sites [40].
This was a post hoc subset analysis, based on
data from phase III, randomized, double-blind,
placebo-controlled trials, so the results should
be interpreted with caution. Since the analysis
was post hoc and not adjusted for multiplicity,
the p values provided in the manuscript are
nominal. Other limitations include short-term
(16 weeks) duration, relatively small number
(N = 263) of dupilumab-treated subjects, and
inability to subdivide assessment of EASI
parameters within each anatomical region:
upper and lower extremity regions cannot be
broken down to assess hand or foot involve-
ment/improvement, and the head and neck
region cannot be broken down to assess facial
involvement/improvement.
CONCLUSIONS
In randomized, placebo-controlled, phase III
trials of dupilumab in children with severe and
adolescents with moderate-to-severe AD, base-
line disease burden was greater in upper and
lower extremities compared with trunk and
head and neck. Treatment yielded comparable
improvements in erythema, edema/papulation,
excoriation, and lichenification across the four
anatomical regions beginning within the first
4 weeks of treatment and sustained through
week 16. Dupilumab was generally well toler-
ated with an acceptable safety profile [22, 23].
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Forté Biosciences, Incyte, LEO Pharma, Menlo
Therapeutics, Pfizer, Pierre Fabre Dermo-Cos-
métique, Regeneron Pharmaceuticals, Inc.,
Sanofi Genzyme, and Valeant. Amy S. Paller
has been an investigator for AbbVie, Anap-
tysBio, Eli Lilly, Incyte, Janssen, Lenus
Pharma, LEO Pharma, Novartis, Regeneron
Pharmaceuticals, Inc., and UCB; and a consul-
tant for AbbVie, Abeona Therapeutics, Almirall,
Asana Biosciences, Boehringer Ingelheim,
BridgeBio Pharma, Dermavant, Dermira, Eli
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